Antihypertensive effects of the novel converting-enzyme inhibitor YS 980 in spontaneously hypertensive rats.
D015097:3-Mercaptopropionic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000803:Angiotensin I / Q000494:pharmacology; D000804:Angiotensin II / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001920:Bradykinin / Q000494:pharmacology; D002395:Catecholamines / Q000097:blood; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D051381:Rats; D013438:Sulfhydryl Compounds; D013844:Thiazoles / Q000627:therapeutic use*; D053778:Thiazolidines
D000806:Angiotensin-Converting Enzyme Inhibitors; D002395:Catecholamines; D013438:Sulfhydryl Compounds; D013844:Thiazoles; D053778:Thiazolidines; D000804:Angiotensin II; C019135:(4R)-3-((2S)-3-mercapto-2-methylpropanoyl)-4- thiazolidinecarboxylic acid; D000803:Angiotensin I; D015097:3-Mercaptopropionic Acid; D001920:Bradykinin